Recommendation for HCV therapy in intravenous drug users. An expert meeting in Berlin, September 5, 2003;Empfehlungen zur HCV-therapie bei i.v. drogengebrauchern. Erarbeitet auf dem von BMGS und RKI organisierten expertentreffen am 5.09.2003 in Berlin

Suchtmedizin in Forschung und Praxis

Volumn 5, Issue 4, 2003, Pages 245-247

  Backmund, Markus ^a   Gölz, Jörg ^a   Kaiser, Stephan ^a   Reimer, Jens ^a   Sarrazin, Christoph ^a   Wedemeyer, Heiner ^a   Marcus, Ulrich ^b   Schaade, Lars ^c  

^a RKI ^*

^b RKI   (Germany)

^c BMGS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; NEUROLEPTIC AGENT; PREDNISOLONE; RIBAVIRIN;

CLINICAL FEATURE; GENOTYPE; GERMANY; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HISTOLOGY; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ABUSE; SHORT SURVEY; TREATMENT CONTRAINDICATION; TREATMENT PLANNING; WORKSHOP;

EID: 0842301353     PISSN: 14375567     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. Backmund M, Meyer K, von Zielonka M, Eichenlaub D (2001): Treatment of hepatitis C infection in injection drug users. Hepatology 34, 188-193
2. Neri S, Bruno CM, Abate G, et al. (2002): Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther 24, 1627-1635
3. Vento S, Garofano T, Renzini C, et al. (1998): Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C. N Engl J Med 338, 286-290
4. Jäckel E, Cornberg M, Wedemeyer H, et al. (2001): Treatment of Acute Hepatitis C with Interferon Alfa-2b. N Engl J Med 345, 1452-1457
5. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M, Pape GR (2003): Acute Hepatitis C: High rate of both spontaneous and treatment induced viral clearance. Gastroenterology 125, 80-88
6. Wedemeyer et al. (eingereicht)
7. Fried MW, Shiffman ML, Reddy KR, et al. (2002): Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. N Engl J Med 347, 975-982
8. Manns MP, McHutchison JG, Gordon SC, et al. (2001): Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286), 958-965
9. Kallinowski, Engler, Ziegler, Bucholz, Jilg & Stremmel, AASLD 2002 (Hepatology 2003, Supplement 2